Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt

Vaccine

Volumn 31, Issue 11, 2013, Pages 1453-1457

  Greenwood, Brian ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGITIS VACCINE; POLYSACCHARIDE TETANUS TOXOID PROTEIN CONJUGATE VACCINE; UNCLASSIFIED DRUG;

AFRICA; ANTIBODY TITER; CELLULAR IMMUNITY; CLIMATE CHANGE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIDEMIC MENINGITIS; EPIDEMIOLOGY; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION PREVENTION; MENINGOCOCCOSIS; MOUTH FLORA; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SEASONAL VARIATION; SEPTICEMIA; SMOKING; VACCINATION;

BIOMEDICAL RESEARCH; BURKINA FASO; CARRIER STATE; DRUG DISCOVERY; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; SENEGAL; VACCINES, CONJUGATE;

EID: 84874444469     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.035     Document Type: Conference Paper

References (16)

1. Lapeyssonnie L. La méningite cérébrospinale en Afrique. Bull World Health Org 1963, 28(Suppl.):3-114.
2. Greenwood B.M. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93:341-353.
3. Molesworth A.M., Thomson M.C., Connor S.J., Cresswell M.P., Morse A.P., Shears P., et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002, 96:242-249.
4. Greenwood B. (2006) 100 years of epidemic meningitis in West Africa - has anything changed?. Trop Med Int Health 2006, 11(7):773-780.
5. Broome C.V., Rugh M.A., Yada A.A., Giat L., Zeltner J.M., Sanborn W.R., et al. Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull World Health Org 1983, 61(2):325-330.
6. Decosas J., Koama J.B. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002, 2(12):763-765.
7. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., Maïnassara H.B., et al. Meningooccal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44(5):657-663.
8. WHO Working Group Control of epidemic meningococcal disease: WHO practical guidelines 1998, Fondation Marcel Merieux, Lyon.
9. Dellicour S., Greenwood B. Impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007, 12(12):1409-1421.
10. Frasch C., Preziosi M.P., LaForce F.M. Development of a group A meningococcal conjugate vaccine: MenAfriVac (TM). Hum Vaccine Immunother 2012, 8(6):715-724.
11. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364(24):2293-2304.
12. Djingarey M.H., Barry R., Bonkoungou M., Tiendrebeogo S., Sebgo R., Kandolo D., et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30(Suppl. 2):B40-B45.
13. Novak R.T., Kambou J.L., Diomandé F.V., Tarbangdo T.F., Ouédraogo-Traoré R., Sangaré L., et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12(10):757-764.
14. Kristiansen PA, Diomandé F, Ky Ba A, Sanou I, Ouédraogo A-S, Ouédraogo R, et al. Impact of serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis; published online October 19th 2012, doi:10.1093/cid/cis892.
15. Nakaya H.I., Li S., Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med 2012, 4(2):193-205.
16. World Health Organization Regional office for Africa. Meningitis Bulletin for week 26; 2012. http://www.meningvax.org/epidemic-updates.php.